Temperature sensitive mutations in the genes encoding the NS1, NS2A, NS3, and NS5 nonstructural proteins of dengue virus type 4 restrict replication in the brains of mice

Archives of Virology

Volumn 148, Issue 5, 2003, Pages 999-1006

  Blaney Jr , Joseph E ^a,b   Manipon, G G ^a   Murphy, B R ^a   Whitehead, S S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b MSC 8007   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANIMALS, SUCKLING; BRAIN; DENGUE VIRUS; GENES, VIRAL; HUMANS; MICE; MUTATION, MISSENSE; PHENOTYPE; TEMPERATURE; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

ANIMALIA; DENGUE VIRUS; DENGUE VIRUS TYPE 4; DNA VIRUSES; FLAVIVIRUS;

EID: 0038394486     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-003-0007-y     Document Type: Article

References (27)

1. Bhamarapravati N, Sutee Y (2000) Live attenuated tetravalent dengue vaccine. Vaccine 18(Suppl 2): 44-47
2. Blaney J, Johnson D, Manipon G, Firestone C, Hanson C, Murphy B, Whitehead S (2002) Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 300: 125
3. Blaney JE Jr, Johnson DH, Firestone CY, Hanson CT, Murphy BR, Whitehead SS (2001) Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice. J Virol 75: 9731-9740
4. Blok J, McWilliam SM, Butler HC, Gibbs AJ, Weiller G, Herring BL, Hemsley AC, Aaskov JG, Yoksan S, Bhamarapravati N (1992) Comparison of a dengue-2 virus and its candidate vaccine derivative: sequence relationships with the flaviviruses and other viruses. Virology 187: 573-590
5. Butrapet S, Huang CY, Pierro DJ, Bhamarapravati N, Gubler DJ, Kinney RM (2000) Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3. J Virol 74: 3011-3019
6. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS (2001) Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 65: 405-413
7. Eckels KH, Harrison VR, Summers PL, Russell PK (1980) Dengue-2 vaccine: preparation from a small-plaque virus clone. Infect Immun 27: 175-180
8. Gubler DJ (1998) Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11: 480-496
9. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, Monath TP (2002) Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298: 146-159
10. Hanley KA, Lee JJ, Blaney JE Jr, Murphy BR, Whitehead SS (2002) Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes. J Virol 76: 525-531
11. Hoke CH Jr, Malinoski FJ, Eckels KH, Scott RM, Dubois DR, Summers PL, Simms T, Burrous J, Hasty SE, Bancroft WH (1990) Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans. Am J Trop Med Hyg 43: 219-226
12. Huang CY, Butrapet S, Pierro DJ, Chang GJ, Hunt AR, Bhamarapravati N, Gubler DJ, Kinney RM (2000) Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 74: 3020-3028
13. Kanesa-Thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, KingA, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn DW, Innis BL, Saluzzo JF, Hoke CH Jr (2001) Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19: 3179-3188
14. Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I, de C, Ramos C, Rico-Hesse R (1999) Dengue virus structural differences that correlate with pathogenesis. J Virol 73: 4738-4747
15. Mangada MN, Igarashi A (1998) Molecular and in vitro analysis of eight dengue type 2 viruses isolated from patients exhibiting different disease severities. Virology 244: 458-466
16. Markoff L, Pang X, Houng HS, Falgout B, Olsen R, Jones E, Polo S (2002) Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J Virol 76: 3318-3328
17. Men R, Bray M, Clark D, Chanock RM, Lai CJ (1996) Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 70: 3930-3937
18. Monath T, Heinz F (1996) Flaviviruses. In: Fields BN, Howley PM, et al. (ed) Fields virology. Lippincott-Raven, Phildadelphia, pp 961-1034
19. Pletnev AG, Bray M, Lai CJ (1993) Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice. J Virol 67: 4956-4963
20. Pletnev AG, Men R (1998) Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4. Proc Natl Acad Sci USA 95: 1746-1751
21. Pletnev AG, Bray M, Hanley KA, Speicher J, Elkins R (2001) Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes. J Virol 75: 8259-8267
22. Pletnev AG, Putnak R, Speicher J, Wagar EJ, Vaughn DW (2002) West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc Natl Acad Sci USA 99: 3036-3041
23. Pryor MJ, Gualano RC, Lin B, Davidson AD, Wright PJ (1998) Growth restriction of dengue virus type 2 by site-specific mutagenesis of virus-encoded glycoproteins. J Gen Virol 79: 2631-2639
24. Puri B, Nelson WM, Henchal EA, Hoke CH, Eckels KH, Dubois DR, Porter KR, Hayes CG (1997) Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells. J Gen Virol 78: 2287-2291
25. Skiadopoulos MH, Durbin AP, Tatem JM, Wu SL, Paschalis M, Tao T, Collins PL, Murphy BR (1998) Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J Virol 72: 1762-1768
26. Skiadopoulos MH, Surman SR, St Claire M, Elkins WR, Collins PL, Murphy BR (1999) Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation. Virology 260: 125-135
27. Whitehead SS, Firestone CY, Karron RA, Crowe JE Jr, Elkins WR, Collins PL, Murphy BR (1999) Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol 73: 871-877